RadNet (NASDAQ:RDNT) Releases Quarterly Earnings Results

RadNet (NASDAQ:RDNT) posted its quarterly earnings results on Sunday. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.10, FiscalAI reports. RadNet had a positive return on equity of 2.77% and a negative net margin of 0.66%.The company had revenue of $622.72 million for the quarter, compared to analysts’ expectations of $610.87 million. During the same quarter in the prior year, the company earned $0.31 earnings per share. The firm’s revenue was up 25.0% on a year-over-year basis.

RadNet Stock Performance

Shares of RadNet stock opened at $77.28 on Tuesday. RadNet has a 12 month low of $50.82 and a 12 month high of $85.84. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.79. The stock has a market cap of $6.08 billion, a PE ratio of -429.31 and a beta of 1.36. The business has a fifty day simple moving average of $61.44 and a 200-day simple moving average of $61.71.

Analysts Set New Price Targets

RDNT has been the topic of a number of recent research reports. Jefferies Financial Group restated a “buy” rating on shares of RadNet in a report on Friday, July 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of RadNet in a report on Friday. Zacks Research lowered RadNet from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Finally, Barclays decreased their price target on RadNet from $70.00 to $65.00 and set an “overweight” rating for the company in a research report on Wednesday, May 20th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, RadNet currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.43.

Insider Buying and Selling at RadNet

In other RadNet news, Director David L. Swartz sold 2,699 shares of RadNet stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $53.89, for a total transaction of $145,449.11. Following the transaction, the director owned 177,013 shares of the company’s stock, valued at $9,539,230.57. The trade was a 1.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Cornelis Wesdorp sold 4,750 shares of RadNet stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $58.11, for a total value of $276,022.50. Following the transaction, the chief executive officer directly owned 69,075 shares in the company, valued at approximately $4,013,948.25. This trade represents a 6.43% decrease in their position. The SEC filing for this sale provides additional information. 5.14% of the stock is currently owned by insiders.

Institutional Trading of RadNet

Several institutional investors have recently made changes to their positions in RDNT. Allworth Financial LP grew its position in RadNet by 346.6% during the third quarter. Allworth Financial LP now owns 393 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 305 shares in the last quarter. Danske Bank A S purchased a new position in shares of RadNet during the 3rd quarter valued at $30,000. Kestra Advisory Services LLC acquired a new position in shares of RadNet in the fourth quarter worth $67,000. State of Wyoming acquired a new position in shares of RadNet in the second quarter worth $58,000. Finally, Smartleaf Asset Management LLC raised its holdings in shares of RadNet by 16.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,586 shares of the medical research company’s stock worth $113,000 after acquiring an additional 225 shares in the last quarter. 77.90% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting RadNet

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: RadNet reported record second-quarter revenue of $622.7 million, up 25% year over year and above the $610.9 million analyst consensus. Adjusted EBITDA increased 22.7% to a quarterly record of $99.7 million. RadNet Q2 financial results
• Positive Sentiment: Adjusted EPS of $0.29 exceeded the $0.19 consensus estimate, helping drive investor confidence despite being below $0.34 in the year-ago quarter. RadNet Q2 earnings metrics
• Positive Sentiment: Advanced imaging volumes rose 21.2% overall and 9.6% at same centers, with MRI, CT and PET/CT driving a favorable shift toward higher-value procedures.
• Positive Sentiment: Management raised full-year Imaging Center guidance for revenue to $2.37–$2.42 billion, Adjusted EBITDA to $345–$358 million and free cash flow to $115–$125 million. RadNet healthcare update
• Positive Sentiment: Digital Health revenue grew 56.5% to $32.4 million, while annual recurring revenue nearly doubled to $105.5 million. A newly FDA-cleared breast-ultrasound AI solution and new health-system contracts could support future growth.
• Neutral Sentiment: The earnings call highlighted ongoing acquisitions, joint ventures and investments in AI infrastructure as key growth initiatives. Cash was $726.3 million and net debt was 1.8 times Adjusted EBITDA. RadNet Q2 earnings call transcript
• Negative Sentiment: Digital Health Adjusted EBITDA declined 27.2% to $2.5 million because of investments in sales, marketing, customer service and implementation. RadNet also remained unprofitable on a GAAP basis, with a first-half net loss of $25.9 million.
• Negative Sentiment: Recent insider activity showed sales rather than purchases, which may temper enthusiasm at elevated valuation levels.

RadNet Company Profile

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.